Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study

Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase... Int J Clin Oncol (2001) 6:271–278 © The Japan Society of Clinical Oncology 2001 ORIGINAL ARTICLE Tokai Gynecologic Oncology Group (Tokai GOG) Kazuo Kuzuya · Hisatake Ishikawa · Toru Nakanishi Fumitaka Kikkawa · Akihiro Nawa · Hidehiko Fujimura Akira Iwase · Yoshitaro Arii · Michiyasu Kawai Sen-ei Hattori · Katsumi Sakakibara · Emiko Sasayama Yoshihito Furuhashi · Takahiro Suzuki Shigehiko Mizutani Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study Received: March 5, 2001 / Accepted: September 6, 2001 Abstract Based on this result, treatment in group B was initiated at Background. A multicenter, phase I study of combination doses of paclitaxel of 160 mg/m and carboplatin AUC 6. therapy with paclitaxel and carboplatin for epithelial ova- While the dose of paclitaxel was escalated to 175 mg/m , the rian cancer was conducted to determine the safety and rec- safety of the combination was confirmed. The most fre- ommended dosages for Japanese women. quent adverse effect was neutropenia, which resolved Methods. Paclitaxel was administered intravenously over a promptly with the appropriate use of granulocyte-colony 3-h period, followed by carboplatin administered intrave- stimulating factor (G-CSF). No other severe hematologic or http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Clinical Oncology Springer Journals

Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study

Loading next page...
 
/lp/springer-journals/optimal-doses-of-paclitaxel-and-carboplatin-combination-chemotherapy-sF7aZBuMDl

References (19)

Publisher
Springer Journals
Copyright
Copyright © 2001 by The Japan Society of Clinical Oncology
Subject
Medicine & Public Health; Oncology; Surgical Oncology; Cancer Research
ISSN
1341-9625
eISSN
1437-7772
DOI
10.1007/s10147-001-8027-7
Publisher site
See Article on Publisher Site

Abstract

Int J Clin Oncol (2001) 6:271–278 © The Japan Society of Clinical Oncology 2001 ORIGINAL ARTICLE Tokai Gynecologic Oncology Group (Tokai GOG) Kazuo Kuzuya · Hisatake Ishikawa · Toru Nakanishi Fumitaka Kikkawa · Akihiro Nawa · Hidehiko Fujimura Akira Iwase · Yoshitaro Arii · Michiyasu Kawai Sen-ei Hattori · Katsumi Sakakibara · Emiko Sasayama Yoshihito Furuhashi · Takahiro Suzuki Shigehiko Mizutani Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: a phase I modified continual reassessment method study Received: March 5, 2001 / Accepted: September 6, 2001 Abstract Based on this result, treatment in group B was initiated at Background. A multicenter, phase I study of combination doses of paclitaxel of 160 mg/m and carboplatin AUC 6. therapy with paclitaxel and carboplatin for epithelial ova- While the dose of paclitaxel was escalated to 175 mg/m , the rian cancer was conducted to determine the safety and rec- safety of the combination was confirmed. The most fre- ommended dosages for Japanese women. quent adverse effect was neutropenia, which resolved Methods. Paclitaxel was administered intravenously over a promptly with the appropriate use of granulocyte-colony 3-h period, followed by carboplatin administered intrave- stimulating factor (G-CSF). No other severe hematologic or

Journal

International Journal of Clinical OncologySpringer Journals

Published: Dec 1, 2001

There are no references for this article.